Sector intelligence and perspective
May 24, 2018
I’m seeking early release from the market watching cell block
Having been incarcerated for defining risks
And I will be grabbing ANY gains to monetize my break-out and beat the exodus
If you were a subscriber, and had read Wednesday’s closing “brief” you’d understand how today’s pre-open indications shed light on share pricing!
Get set for a mixed open …
May 17, 2018
Q1/18 financial results also known as (AKA) earnings is a ‘scorecard’ of public stem, cell, gene therapies and editing, regenerative therapy and a couple of CNS and RNAi companies.
The current LPS (loss per share) standings reflect the universes’ investing status; then add in their cash position for a better snapshot!
By analyzing these comparisons, investors can begin to gauge the financial health versus the scientific opportunity and whether or not it deserves their investment.
May 23, 2018
Ended with an algorithmic finger in the dike (?) and closed to the upside
With relative strength (lines) trending upward
Still my concern is low volume as
… The upside was broader (range of +$0.01 to -$5.81) in 28 equities while the downside ranged weakly and top-heavy (-$0.01 to -$8.49) was in 16 stocks
Pre-open indications: 2 HIT and 1 MISS ($0.17 cents)
We keep you informed, if you want to be knowledgeable of the “bones” of the sector - be a subscriber to understand what you need to do in tomorrow’s market. Let the “numbers” speak since sentiment is capricious!
April 23, 2018
PSTI closed Friday at $1.20 (-$0.04) and is UP +$0.04 in the pre-market The 5-year joint project was granted $2.5 million from the U.S. NIH
April 16, 2018
Closed down -$0.04 and is up +$0.0 or +7.28% to $1.09 ONVO continues to map out a range of relevant conditions for creating NASH, including all components of the disease (fat accumulation, inflammation and fibrosis).
April 12, 2018
ONVO closed down -$0.01 to $1.01 and is UP +$0.04 or +$0.04 or +3.96 These new data points provide strong support for the application of the NAFLD model to high-value drug profiling, including the possible creation of patient or population-specific model variants.
The process of calling out our grading of covered companies to rank and review the facts in evidence together with analysis, opinion and objective recommendation.
5 hours 3 min ago
RegMed Investors’ (RMi) pre-open; long holiday weekend ahead
© 2018 RegMed Investors (regmedinvestors.com), all rights are reserved.
RegMed Investors (RMi) or Regmedinvestors.com content is the intellectual property of Henry McCusker. Any copying, republication or redistribution of RMI’s content, including by framing or similar means, is expressly prohibited without the prior written consent of Scimitar; who also shall not be liable for any errors or delays in content, or for any actions taken in reliance thereon. For additional information on other Scimitar media services or reposting please email hwm@regmedinvestors.com.
The information included above as well as individual companies and/or securities mentioned should be construed as guidance in RMi reviews.
The facts stated and the opinions given in this publication are based on data and information considered to be reliable and have been carefully worked into my qualitative analyses and prognoses. However, no guarantee can be given as to their fairness, accuracy or completeness.
Henry McCusker, the editor and publisher of RegMed Investors does not hold or have positions in securities referred to in this publication.
